Related Experiment Video
Updated: Dec 28, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Overexpression of IGF2BP3 as a Potential Oncogene in Ovarian Clear Cell Carcinoma
Huidi Liu1,2,3,4,5, Zheng Zeng1,2,3, Mitra Afsharpad6
1Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin, China.
Abstract:
Ovarian Clear Cell Carcinoma (OCCC) displays distinctive clinical and molecular characteristics and confers the worst prognosis among all ovarian carcinoma histotypes when diagnosed at advanced stage, because of the lack of effective therapy. IGF2BP3 is an RNA binding protein that modulates gene expression by post-transcriptional action. In this study, we investigated the roles of IGF2BP3 in the progression of OCCC. We used 328 OCCCs from the AOVT (the Alberta Ovarian Tumor Type study) and the COEUR (the Canadian Ovarian Experimental Unified Resource) cohorts to elucidate the associations between IGF2BP3 expression and clinicopathological parameters, with positive IGF2BP3 expression defined as diffuse block staining, being more frequently observed at stage III (P = 0.0056) and significantly associated with unfavorable overall survival (HR = 1.59, 95% CI 1.09-2.33) in multivariate analysis. IGF2BP3 mRNA gene expression was markedly increased in OCCC cell lines compared to normal tissues such as ovarian surface epithelium. We chose two IGF2BP3-overexpressing cell lines ES2 and OVMANA for in vitro and in vivo knockdown experiments. The proliferation and viability of both cell lines were significantly inhibited by two IGF2BP3 siRNAs and similar suppression was observed in cell migration and invasion by Wound Healing and Transwell assays. The percentage of apoptotic cancer cells was enhanced by both IGF2BP3 siRNAs. In vivo experiments showed significantly reduced sizes of tumors when treated with IGF2BP3 siRNA compared to controls. Furthermore, cancer metastasis-indicators MMP2 and MMP9 proteins were down-regulated. In conclusion, our study shows that IGF2BP3 expression is a promising biomarker for prognostication of women diagnosed with OCCC with multiple effects on key cell functions, supporting its role as an important cellular regulator with potential oncogenic activity, and as a potential target for future intervention strategies.
Insights
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) promotes ovarian clear cell carcinoma (OCCC) progression. Targeting IGF2BP3 inhibits OCCC cell proliferation, migration, invasion, and tumor growth, suggesting it as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian Clear Cell Carcinoma (OCCC) has a poor prognosis due to limited effective therapies.
- Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) is an RNA-binding protein influencing gene expression post-transcriptionally.
Purpose of the Study:
- To investigate the role of IGF2BP3 in OCCC progression.
- To determine the association between IGF2BP3 expression and clinicopathological parameters in OCCC.
- To evaluate IGF2BP3 as a potential therapeutic target for OCCC.
Main Methods:
- Analysis of 328 OCCC samples from the AOVT and COEUR cohorts.
- Assessment of IGF2BP3 expression and its correlation with clinicopathological parameters and survival.
- In vitro and in vivo knockdown experiments using IGF2BP3-overexpressing OCCC cell lines (ES2, OVMANA) with siRNAs.
- Evaluation of cell proliferation, viability, migration, invasion, and apoptosis.
- Measurement of metastasis-related proteins MMP2 and MMP9.
Main Results:
- Positive IGF2BP3 expression was more frequent in Stage III OCCC and associated with unfavorable overall survival.
- IGF2BP3 mRNA expression was significantly increased in OCCC cell lines compared to normal ovarian surface epithelium.
- IGF2BP3 knockdown inhibited OCCC cell proliferation, viability, migration, and invasion, and enhanced apoptosis.
- In vivo tumor growth was significantly reduced following IGF2BP3 siRNA treatment.
- Down-regulation of MMP2 and MMP9 proteins was observed after IGF2BP3 knockdown.
Conclusions:
- IGF2BP3 expression is a potential prognostic biomarker for OCCC.
- IGF2BP3 plays a significant role in OCCC progression by affecting key cellular functions.
- IGF2BP3 represents a potential therapeutic target for OCCC intervention strategies.
More Related Videos
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
12:42Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
Published on: August 28, 2012
Related Concept Videos
Mitogens and the Cell Cycle
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Induced Pluripotent Stem Cells
Somatic...